Wall Street Zen downgraded shares of CVRx (NASDAQ:CVRX – Free Report) from a sell rating to a strong sell rating in a research note released on Sunday morning,Wall Street Zen reports.
Other research analysts have also recently issued reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of CVRx in a research report on Friday, October 30th. Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Friday, August 7th. William Blair lowered shares of CVRx from an “outperform” rating to a “market perform” rating in a report on Friday, November 6th. Cantor Fitzgerald cut their price objective on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating for the company in a research note on Monday, August 17th. Finally, Canaccord Genuity Group lowered shares of CVRx from a “buy” rating to a “hold” rating and reduced their target price for the company from $5.00 to $2.00 in a report on Friday, November 6th. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $2.70.
Get Our Latest Analysis on CVRX
CVRx Price Performance
CVRX opened at $0.61 on Friday. The stock has a 50-day moving average price of $1.76 and a 200-day moving average price of $4.94. CVRx has a 12-month low of $0.57 and a 12-month high of $10.28. The company has a current ratio of 6.80, a quick ratio of 5.71 and a debt-to-equity ratio of 4.24. The stock has a market capitalization of $17.41 million, a P/E ratio of -0.30 and a beta of 0.81.
CVRx (NASDAQ:CVRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The firm had revenue of $13.83 million for the quarter, compared to analysts’ expectations of $13.93 million. CVRx had a negative net margin of 88.28% and a negative return on equity of 208.45%. Equities analysts predict that CVRx will post -2.04 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CVRx
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Deutsche Bank AG bought a new position in CVRx during the 2nd quarter worth approximately $62,000. Renaissance Technologies LLC purchased a new position in CVRx in the 1st quarter worth approximately $183,000. Bank of America Corp DE purchased a new position in CVRx in the 2nd quarter worth approximately $102,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in CVRx in the second quarter valued at approximately $107,000. Finally, Empowered Funds LLC bought a new stake in CVRx in the third quarter valued at approximately $63,000. Institutional investors own 75.27% of the company’s stock.
Key CVRx News
These are some of the CVRX news items that stood out recently:
- Neutral Sentiment: CVRx plans to participate in a Piper Sandler healthcare conference on Dec. 2. The announcement provides an opportunity for management to address investors, but no new business or financial developments were disclosed. Conference announcement
- Negative Sentiment: Several law firms publicized an already-filed securities class action covering investors who bought shares from July 25, 2023, through Aug. 6, 2026; the lead-plaintiff deadline is Jan. 8, 2027. The suit alleges CVRx’s disclosures understated risks related to Barostim marketing and kickbacks. These are allegations, not established findings, but the litigation adds uncertainty and potential costs. Class action notice
- Negative Sentiment: Investor alerts also point to a Department of Justice civil investigative demand, sharply reduced revenue guidance, sales-force disruption and the termination of the chief revenue officer as events underlying the lawsuit. Together, these issues heighten concerns about CVRx’s commercial execution and regulatory exposure. Investor alert
CVRx Company Profile
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
See Also
- Five stocks we like better than CVRx
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
